Cogent Biosciences, Inc. COGT
NASDAQ · United States · Health Technology
$32.02+0.36 (+1.14%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s valuation stacks up against the company’s book value. Over the past 5 years the stock is up about 2.7x. This puts real pressure on the question of whether the current price is still in line with what its...
Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased recently, with the 30 day share price return down 13.3% and the 90 day share price return down 17.4%. However, the 1 year total shareholder return of 137.1% suggests earlier optimism around its broader...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal APEX trial data showing clinically meaningful responses and durable clinical activity in Advanced Systemic Mastocytosis, while parallel NDA reviews in NonAdvanced SM and GIST point to a broader...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.